updated fda mrd guidelines for hematological malignancies
Published 4 years ago • 189 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
2:35
an update on mrd assessment and novel techniques used in the treatment of hematological malignancies
-
0:44
the recent fda approval of ponatinib for ph all following success in the phallcon trial
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
1:25
recent fda approval of exa-cel & lovo-cel for patients with scd
-
1:02:57
fda quality systems regulation requirements - regulatory documents explained
-
1:09:32
dhf, dmr, dhr and tf regulatory documents explained
-
59:20
fda qsr requirements for dmr & dhr
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
2:22
determining how to optimally use fda-approved drugs in chronic gvhd
-
0:46
the importance of mrd assessment in all phases of all treatment
-
1:40
updates on the use of molecular monitoring to detect mrd in aml
-
2:22
next-generation methodologies: the future for mrd monitoring in all?
-
2:55
current and emerging treatments for mf: an update from ash 2023
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:01
elm-2 trial: using ctdna and mrd to measure odronextamab outcomes in dlbcl and fl
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:48
developing effective methods to study qol in clinical trials in mds
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo